Table 3.
Characteristics of interview participants
| Participant ID | Role | Trial(s) involved in (subject area), where applicable |
|---|---|---|
| 01 | TSC Chair | 1, 2 (oncology) |
| 02* | Project lead | 1, 5 (oncology) |
| 03 | TSC coordinator #1 | 1, 2 (oncology) |
| 04 | TSC coordinator #2 | 1, 2 (oncology) |
| 05* | Sponsor representative | 1, 2 (oncology) |
| 06* | Sponsor representative | 1, 2 (oncology) |
| 07* | Trial manager | 1 (oncology) |
| 08* | CI | 2 (oncology) |
| 09* | Trial manager | 2 (oncology) |
| 10* | Trial manager | 3 (arthritis) |
| 11* | Statistician | 3 (arthritis) |
| 12* | Trial manager | 3 (arthritis) |
| 13 | Statistician | 3 (arthritis) |
| 14 | CI | 3 (arthritis) |
| 15 | TSC Chair | 3 (arthritis) |
| 16* | Trial manager | 4 (frailty) |
| 17 | TSC Chair | 4 (frailty) |
| 18 | CI | 4 (frailty) |
| 19 | TMG Chair | 4 (frailty) |
| 20* | TMG member | 4 (frailty) |
| 21* | Trial manager | 5 (oncology) |
| 22 | Statistician | 5 (oncology) |
| 23* | CI | 5 (oncology) |
| 24* | Independent TSC member | 5 (oncology) |
| 25 | Independent TSC member | 5 (oncology) |
| 26* | Trial manager | 6 (urology) |
| 27* | Trial manager | 6 (urology) |
| 28* | Statistician | 6 (urology) |
| 29* | CI | 6 (urology) |
| 30* | TSC Chair | 6 (urology) |
| 31* | Independent TSC member | 6 (urology) |
| 32* | TMG member | 6 (urology) |
| 33* | Trial manager | 7 (psychology) |
| 34* | CI | 7 (psychology) |
| 35* | Public contributor | 7 (psychology) |
| 36* | TSC Chair | 7 (psychology) |
| 37* | Statistician | 7 (psychology) |
| 38* | TSC Member | 7 (psychology) |
| 39 | CTU Director | 7 (psychology) |
| 40* | Trial manager | 7 (psychology) |
| 41* | Trial manager | 8 (oncology) |
| 42* | Chair | 8 (oncology) |
| 43a* | Public contributor | 8 (oncology) |
| 43b* | Public contributor | 8 (oncology) |
| 44 | Statistician | 8 (oncology) |
| 45* | Sponsor representative | 8 (oncology) |
| 46* | CI of other trial/member of TSCs | n/a |
| 47* | Funder representative | n/a |
| 48 | Sponsor representative | n/a |
| 49* | Funder representative | n/a |
| 50* | Statistician | n/a |
| 51* | Funder representative | n/a |
CI Chief Investigator, CTU clinical trials unit, TMG trial management group, TSC trial steering committee
*Interviewee discussed PPI